Skip to content

Study · Randomized controlled trial · n = 20 · 2019

5 results

Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.

Farr OM, Upadhyay J, Rutagengwa C, DiPrisco B, Ranta Z, Adra A, Bapatla N, Douglas VP, Douglas KAA, Nolen-Doerr E, Mathew H, Mantzoros CS

Diabetes, obesity & metabolism8 Aug 2019Cited by 52 (Europe PMC)

PMID31282006 (opens in a new tab)PMCIDPMC6800581 (opens in a new tab)DOI10.1111/dom.13827 (opens in a new tab)PepBankPUB-31282006
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide 3.0 mg led to a 2.7% greater weight loss than placebo.

    In plain wordsIn adults with obesity, liraglutide 3.0 mg led to more weight loss than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight change (placebo-subtracted)
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · after 5 weeks of dose escalationAs given in this study (human).

    Measurements

    Placebo-subtracted weight change
    −2.7%
    liraglutide 3.0 mg

    Source sentences

    Summary
    While using liraglutide, patients lost more weight (placebo-subtracted -2.7%; P < .001)
    1 context sentence
    Summary · context
    A total of 20 participants with obesity were treated with placebo and liraglutide (3.0 mg) in the context of a randomized, placebo-controlled, double-blind, cross-over trial after 5 weeks of dose escalation.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, liraglutide 3.0 mg lowered fasting glucose versus placebo.

    In plain wordsIn adults with obesity, liraglutide 3.0 mg lowered fasting glucose compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting glucose
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    3.0 mg · after 5 weeks of dose escalationAs given in this study (human).

    Source sentences

    Summary
    had decreased fasting glucose (P < .001)
    1 context sentence
    Summary · context
    A total of 20 participants with obesity were treated with placebo and liraglutide (3.0 mg) in the context of a randomized, placebo-controlled, double-blind, cross-over trial after 5 weeks of dose escalation.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with obesity, cholesterol levels were reported as improved while using liraglutide 3.0 mg; the abstract gives no values and no clear comparison.

    In plain wordsIn adults with obesity, cholesterol levels were reported as improved while using liraglutide 3.0 mg, with no numbers given.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedCholesterol levels
    Study

    n = 20

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    3.0 mg · after 5 weeks of dose escalationAs given in this study (human).

    Source sentences

    Summary
    showed improved cholesterol levels.
    1 context sentence
    Summary · context
    A total of 20 participants with obesity were treated with placebo and liraglutide (3.0 mg) in the context of a randomized, placebo-controlled, double-blind, cross-over trial after 5 weeks of dose escalation.
  4. 04HumanRandomized controlled trialMechanism

    In adults with obesity, brain activation in response to food images was not altered by liraglutide versus placebo in the uncontrolled analysis.

    In plain wordsIn adults with obesity, liraglutide did not change brain activity in response to food images compared with placebo in the main analysis.

    Peptide
    Liraglutide
    Outcome
    No significant changeBrain activation to food images (uncontrolled analysis)
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    3.0 mg · after 5 weeks of dose escalationAs given in this study (human).

    Source sentences

    Summary
    In an uncontrolled analysis, brain activation in response to food images was not altered by liraglutide vs placebo.
    1 context sentence
    Summary · context
    A total of 20 participants with obesity were treated with placebo and liraglutide (3.0 mg) in the context of a randomized, placebo-controlled, double-blind, cross-over trial after 5 weeks of dose escalation.
  5. 05HumanRandomized controlled trialMechanism

    In adults with obesity, when controlled for BMI/weight, liraglutide increased activation of the right orbitofrontal cortex in response to food cues.

    In plain wordsIn adults with obesity, after accounting for weight change, liraglutide increased activity in a brain reward area in response to food images.

    Peptide
    Liraglutide
    Outcome
    IncreaseRight orbitofrontal cortex activation to food cues (controlled for BMI/weight)
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    3.0 mg · after 5 weeks of dose escalationAs given in this study (human).

    Source sentences

    Summary
    When controlled for BMI/weight, liraglutide increased activation of the right orbitofrontal cortex (OFC) in response to food cues (P < .016, corrected for multiple comparisons).
    1 context sentence
    Summary · context
    A total of 20 participants with obesity were treated with placebo and liraglutide (3.0 mg) in the context of a randomized, placebo-controlled, double-blind, cross-over trial after 5 weeks of dose escalation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.